TrianglePemigatinib (NCT06728410)
Pemigatinib trial for Intrahepatic Cholangiocarcinoma (NCT06728410). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced intrahepatic bile-duct cancer carrying an FGFR2 fusion or rearrangement, after gemcitabine, cisplatin and checkpoint treatment. Progression, chemotherapy intolerance, or six months with stable or responding disease can qualify. Prior FGFR inhibitors are excluded.
The idea: combine pemigatinib, which blocks FGFR growth signaling, with durvalumab, which blocks PD-L1 immune suppression. Pemigatinib tablets follow two weeks on, one week off; durvalumab is infused every three weeks. Researchers measure tumor responses and safety.
This phase 2 study plans 38 patients. Mehmet Akce leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.